IL130784A0 - Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same - Google Patents
Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the sameInfo
- Publication number
- IL130784A0 IL130784A0 IL13078497A IL13078497A IL130784A0 IL 130784 A0 IL130784 A0 IL 130784A0 IL 13078497 A IL13078497 A IL 13078497A IL 13078497 A IL13078497 A IL 13078497A IL 130784 A0 IL130784 A0 IL 130784A0
- Authority
- IL
- Israel
- Prior art keywords
- medicament
- patient
- treating
- manufacture
- pharmaceutical compositions
- Prior art date
Links
- 208000024781 Immune Complex disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3467397P | 1997-01-10 | 1997-01-10 | |
| PCT/US1997/023482 WO1998030240A1 (en) | 1997-01-10 | 1997-12-31 | Treatment of lupus nephritis with anti-cd40l compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL130784A0 true IL130784A0 (en) | 2001-01-28 |
Family
ID=21877889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13078497A IL130784A0 (en) | 1997-01-10 | 1997-12-31 | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030031668A1 (cs) |
| EP (2) | EP1357131A3 (cs) |
| JP (1) | JP2001508441A (cs) |
| KR (2) | KR20000070034A (cs) |
| CN (2) | CN1572325A (cs) |
| AU (1) | AU5709798A (cs) |
| BR (1) | BR9714523A (cs) |
| CA (1) | CA2277222A1 (cs) |
| CZ (1) | CZ297680B6 (cs) |
| EA (2) | EA006314B1 (cs) |
| EE (1) | EE9900273A (cs) |
| HU (1) | HUP0000833A3 (cs) |
| IL (1) | IL130784A0 (cs) |
| IS (1) | IS5100A (cs) |
| NO (1) | NO993274L (cs) |
| NZ (1) | NZ337072A (cs) |
| PL (1) | PL190663B1 (cs) |
| TR (7) | TR200001247T2 (cs) |
| WO (1) | WO1998030240A1 (cs) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| JP2002510643A (ja) * | 1998-04-03 | 2002-04-09 | トラスティーズ・オブ・ダートマス・カレッジ | 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用 |
| IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| ES2277460T3 (es) | 1998-12-14 | 2007-07-01 | Genetics Institute, Llc | Cadena del receptor de la citoquina. |
| US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
| US20010055593A1 (en) * | 2000-03-14 | 2001-12-27 | Joseph Sypek | Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| US20020058029A1 (en) * | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| CN100369932C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人cd154单克隆抗体及其应用 |
| DK2367849T3 (en) * | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | METHOD OF TREATING NEURODEGENERATIVE DISEASES |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| WO2012031122A2 (en) * | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
| CA2920686C (en) | 2013-09-13 | 2022-12-06 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
| IL320195A (en) | 2013-09-13 | 2025-06-01 | Genentech Inc | Methods and compositions containing purified recombinant polypeptides |
| EP3191131A4 (en) | 2014-08-21 | 2018-09-05 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| US20180251559A1 (en) * | 2015-08-31 | 2018-09-06 | Julie DeMartino | Methods for the Modulation of LGALS3BP to Treat Systemic Lupus Erythematosus |
| AU2018271915B2 (en) | 2017-05-24 | 2025-03-27 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| JP2000503659A (ja) * | 1996-01-16 | 2000-03-28 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティー オブ ニューヨーク | 自己抗体の沈着以外の開始点を有する炎症性腎疾患を処置するためのｔ―ｂａｍ（ｃｄ４０―ｌ）技術の治療的適用 |
| WO1997034473A1 (en) * | 1996-03-21 | 1997-09-25 | The Trustees Of Columbia University In The City Of New York | Craf1 (traf-3) isoforms and uses thereof |
-
1997
- 1997-12-31 TR TR2000/01247T patent/TR200001247T2/xx unknown
- 1997-12-31 WO PCT/US1997/023482 patent/WO1998030240A1/en not_active Ceased
- 1997-12-31 EP EP03014404A patent/EP1357131A3/en not_active Withdrawn
- 1997-12-31 TR TR2000/01246T patent/TR200001246T2/xx unknown
- 1997-12-31 BR BR9714523-8A patent/BR9714523A/pt not_active Application Discontinuation
- 1997-12-31 HU HU0000833A patent/HUP0000833A3/hu unknown
- 1997-12-31 CN CNA2004100353620A patent/CN1572325A/zh active Pending
- 1997-12-31 EA EA199900636A patent/EA006314B1/ru not_active IP Right Cessation
- 1997-12-31 KR KR1019997006253A patent/KR20000070034A/ko not_active Ceased
- 1997-12-31 EE EEP199900273A patent/EE9900273A/xx unknown
- 1997-12-31 PL PL97334495A patent/PL190663B1/pl not_active IP Right Cessation
- 1997-12-31 JP JP53090198A patent/JP2001508441A/ja not_active Ceased
- 1997-12-31 KR KR1020057013113A patent/KR100618081B1/ko not_active Expired - Fee Related
- 1997-12-31 CA CA002277222A patent/CA2277222A1/en not_active Abandoned
- 1997-12-31 NZ NZ337072A patent/NZ337072A/xx unknown
- 1997-12-31 TR TR2000/01251T patent/TR200001251T2/xx unknown
- 1997-12-31 TR TR2000/01249T patent/TR200001249T2/xx unknown
- 1997-12-31 AU AU57097/98A patent/AU5709798A/en not_active Abandoned
- 1997-12-31 IL IL13078497A patent/IL130784A0/xx unknown
- 1997-12-31 TR TR1999/02191T patent/TR199902191T2/xx unknown
- 1997-12-31 TR TR2000/01248T patent/TR200001248T2/xx unknown
- 1997-12-31 CN CN97181948A patent/CN1247472A/zh active Pending
- 1997-12-31 CZ CZ0244499A patent/CZ297680B6/cs not_active IP Right Cessation
- 1997-12-31 EA EA200501076A patent/EA200501076A1/ru unknown
- 1997-12-31 TR TR2000/01250T patent/TR200001250T2/xx unknown
- 1997-12-31 EP EP97953325A patent/EP0948355A1/en not_active Withdrawn
-
1999
- 1999-06-30 IS IS5100A patent/IS5100A/is unknown
- 1999-07-01 NO NO993274A patent/NO993274L/no not_active Application Discontinuation
-
2002
- 2002-09-27 US US10/260,639 patent/US20030031668A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/527,700 patent/US20070190053A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130784A0 (en) | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same | |
| HUP0101293A3 (en) | Aspb28-human insulin comprising pharmaceutical composition administered by inhalation and their use | |
| IL114586A (en) | Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same | |
| CY2007001I2 (el) | Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη | |
| EP0745401A3 (en) | Medication inhaler | |
| ZA942804B (en) | Oral drug delivery compositions and methods | |
| EP0770021A4 (en) | DISTRIBUTOR OF MEDICINES IN UNIT DOSES USING APPLICATORS | |
| EP0466566A3 (en) | Coated solid medicament form having releasebility in large intestine | |
| IL118483A (en) | Compounds for use in the preparation of medicaments for inhibiting vascular smooth muscle cell migration and pharmaceutical formulations containing them | |
| HUP0300836A3 (en) | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same | |
| IL119552A0 (en) | Substituted sulfonimidamides processes for their preparation their use as a medicament or diagnostic and medicaments comprising them | |
| IL123013A0 (en) | Five-membered heterocycles having biphenylsulfonyl substitution process for their preparation their use as a medicament or diagnostic and medicaments comprising them | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| IL119894A (en) | Use of thiazolidine in the preparation of a medicament for the treatment of osteoporosis | |
| GB9418064D0 (en) | Medicament administration inhaler | |
| IL125743A (en) | Medicinal preparation containing an active medical substance with homeopathic potentiation | |
| ZA984268B (en) | Method and composition for administering taxanes orally to human patients | |
| ZA9711129B (en) | New analogues of camptothecin their medical application and the pharmaceutical substances that contain them | |
| EP0438147A3 (en) | Pharmaceutical compositions and dosage forms for the oral administration of calcitonin | |
| HUP9802897A3 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
| HUP0001526A3 (en) | Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions | |
| HUP0004410A3 (en) | A one dose syringe, comprising a freeze-dried protein composition, for administering of a volume less than 0,5ml | |
| IL164513A0 (en) | Pyrazolopyrimidines, pharmaceutical compositions containing them, and their use in the preparation of medicaments | |
| IL91451A0 (en) | Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction | |
| ZA975168B (en) | Devices intended for the transdermic administration of trimegestone their preparation process and their use as medicaments |